Grail reported Q1 revenue up 28% year over year, driven by growth in its Galleri multi-cancer early detection blood test. Revenue tied to Galleri reached $39.8M, and test volume increased 37% with volume rising to more than 56,000 tests, while the company said new prescribers and ordering channels expanded during the quarter. Grail executives highlighted continued strength across brick-and-mortar providers, digital health customers and employer-driven benefits. The company also pointed to Epic integration work designed to streamline Galleri ordering through electronic health record workflows later in 2026. While Grail noted uncertainty among customers following the preliminary NHS-Galleri results reported earlier in the quarter, management framed the immediate commercial priority as scaling sales force readiness ahead of the final dataset presentation.